Floatz logo

cd22 car-transduced t cells

Refractory Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer CenterCell therapyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

211 Active assets in the Refractory Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Weill Medical College of Cornell University
Phase 2BBB
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
Apg-2575
Henan Cancer Hospital
Phase 3BBB
Fludarabine
Roswell Park Cancer Institute
Phase 3BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 4BBB

View all 50 →

Same molecule, other indications

cd22 car-transduced t cells is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B-cell adult acute lymphocytic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
Lymphoma, B-CellDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →